Novo Nordisk AS Class B NOV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GLP-1 drugs could ease back and knee pain, but doctors say there are risks for older adults
-
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
-
Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
-
Taking Ozempic and worried about vision loss? This test can help you understand your risk.
-
Novo Nordisk strikes second licensing deal since frosty capital-markets day
-
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
-
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring
-
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
Trading Information
- Previous Close Price
- €34.92
- Day Range
- €34.76–35.80
- 52-Week Range
- €30.29–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 4.41B
- Market Cap
- €157.02B
- Volume/Avg
- 7,557 / 168,936
Key Statistics
- Price/Earnings (Normalized)
- 9.21
- Price/Sales
- 3.59
- Dividend Yield (Trailing)
- 4.40%
- Dividend Yield (Forward)
- 4.40%
- Dividend Payment Schedule
- Mar, Aug
- Total Yield
- 4.90%
Company Profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 68,794
- Website
- https://www.novonordisk.com
Competitors
Valuation
|
Metric
|
NOV
|
RHHBY
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.21 | 21.17 | 12.60 |
Price/Book Value | 5.32 | 9.65 | 1.29 |
Price/Sales | 3.59 | 4.97 | 1.81 |
Price/Cash Flow | 8.60 | 15.57 | 7.70 |
Price/Earnings
NOV
RHHBY
SNY
Financial Strength
|
Metric
|
NOV
|
RHHBY
|
SNY
|
|---|---|---|---|
Quick Ratio | 0.64 | 0.80 | 0.21 |
Current Ratio | 0.87 | 1.23 | 1.12 |
Interest Coverage | — | 13.49 | 9.10 |
Quick Ratio
NOV
RHHBY
SNY
Profitability
|
Metric
|
NOV
|
RHHBY
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 21.31% | 15.81% | 5.78% |
Return on Equity (Normalized) | 59.99% | 48.77% | 10.69% |
Return on Invested Capital (Normalized) | 34.79% | 23.90% | 8.35% |
Return on Assets
NOV
RHHBY
SNY
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|&#@Tr$B | LOCK|^< | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|m!T$LHg | LOCK|sTZ | $658B | |||
| AbbVie Inc
ABBV
| LOCK|@@F?sJm | LOCK|<M | $521B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|Ts?PF&sf | LOCK|#TW | $391B | |||
| Merck & Co Inc
MRK
| LOCK|W?&KC$ | LOCK|>FV | $369B | |||
| Novartis AG ADR
NVS
| LOCK|S@mQL$M | LOCK|^p | $307B | |||
| AstraZeneca PLC
AZN
| LOCK|Pr&fR$>m | LOCK|Sb | $290B | |||
| Amgen Inc
AMGN
| LOCK|lhs##DF | LOCK|WTT | $252B | |||
| Gilead Sciences Inc
GILD
| LOCK|DWc<$f@ | LOCK|sgV | $212B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Q$@P>D< | LOCK|F&< | $176B |
United States